Transcutaneous Continuous Hemoglobin MeasurementSpHbNCT04506957
Non-invasive Continuous Total Hemoglobin Measurement by Pulse CO-Oximetry
An observational study of Transcutaneous Continuous Hemoglobin Measurement, run by Klinik Hirslanden, Zurich.
Trial summary
This study is a data collection/sampling project for transcutaneous continuous Pulse CO-Oximetry and accessories (SW-Version Radical-7® Pulse CO-Oximeter with the Masimo rainbow SETTM, V1.6.2.4i Masimo Corp., Irvine, CA, USA, and the RD rainbow SET-2, Rev-O Fingersensor). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Transcutaneous Continuous Hemoglobin Measurement
- What is being tested?
- Pulse CO-Oximetry Hemoglobin measurement transcutaneous
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2020to 30 Jun 2022
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for major spine surgery
Who may be able to join
- Patients scheduled for major spine surgery
- Written consent of the participation after clarification about the study
Who cannot join
- No consent to participate
- No German comprehension
- Black skin patients
- Patients with COVID-19 illness
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Non-invasive Continuous Total Hemoglobin Measurement by Pulse CO-Oximetry in Major Spine Surgery
This study is a data collection/sampling project for transcutaneous continuous Pulse CO-Oximetry and accessories (SW-Version Radical-7® Pulse CO-Oximeter with the Masimo rainbow SETTM, V1.6.2.4i Masimo Corp., Irvine, CA, USA, and the RD rainbow SET-2, Rev-O Fingersensor). The device received the CE Mark in 2012 and is approved by the Swiss Medic for clinical use. The Radical-7 device isolates multiple (7+) wavelengths of light of arterial signals using adaptive filters. It provides continuous noninvasive monitoring of arterial oxygen saturation (RadSpO2), pulse rate (RadPR), carboxyhaemoglobin saturation (SpCO), methaemoglobin saturation (SpMET), total haemoglobin concentration in g/dl (SpHb) and/or respiration rate (RRa). Additionally, Low Signal IQ (Low SIQ), Perfusion Index (PI), Pleth Variability Index (PVI), total arterial oxygen content (SpOC), Haematocrit (SpHCT), Signal identification Quality (SIQa), Respiration Indicator (RI) are displayed.The purpose of this prospective study is to investigate the reliability of non-invasive continuously measured SpHb by the Masimo Radical-7® Pulse co-oximeter (Radical 7 device) under steady state conditions by comparison against simultaneously invasive measured arterial haemoglobin concentrations (CoOxHb) in major spine surgery patients, in which high blood loss was expected
Read the detailed description
The objective of this investigation is the comparison of CoOxHb, HCT and SaO2 values of a blood gas analyzer (ABL 825, Radiometer Medical A/S) with simultaneously measured SpHb values of the Radical 7 device during the procedure of major spine surgery.
The primary endpoint of the study is the reliability of SpHb to detect CoOxHb and its changes during the process Secondary endpoint is the reliability of RadSpO2, RadPR, SpHCT and SpMET to detect SaO2, PR, HCT and MetHb and its changes during the process.
Inclusion criteria:
- Patients scheduled for major spine surger
- Age 18 years and older
- Written consent of the participation after clarification about the study
Exclusion criteria:
- No consent to participate
- No German comprehension
- Black skin patients
- Patients with COVID-19 illness All patients were monitored based on the institutional routine monitoring for major spine surgery (continuous 2-channel electrocardiogram, a continuous invasive arterial blood pressure monitoring via fluid-filled cather system, inserted in the radial artery mainly of the non-dominant hand, SpO2, and in the case of high-risk patient a triple-lumen central venous line). Then a single use finger sensor (MasimoSet RD rainbow SET SpHb SpMet-Sensor) is attahed to the ring finger of the hand, where the catheter is introduced in the radial artery.
During the surgery routinely, arterial blood samples are drawn before induction of Anaesthesia, every 45 min and after acute blood loss during surgery. With each blood sample for a blood gas analysis the SpHb, SpMet, PI, PVI and the low SQI are recorded.
No additional blood sampling is necessary to perfom this investigation
50 patients will be included and the duration of the study is 24 month's Sample size calculation was performed with the StatsDirect Statistical Software Version 2.8.0 2013 (StatsDirect Ltd, Altrincham, UK) and revealed a sample size of 95 paired SpHb and CoOxHb measurements to achieve a power of 0.9, α = 0.05 to detect a mean difference (bias) of CoOxHb and SpHb of 0.50 g/dl with an estimated standard deviation (SD) of 1.0g/dl. The mean difference is determined based on previous investigations. Continuous variables are tested for normal distribution with the Kolmogorov-Smirnow test. Normally distributed data are expressed as mean ± standard deviation (SD); median, interquartile range (IQR ; 25th to 75th percentile) and [maximum] are specified when the data were not normally distributed. Categorical variables are presented as number and percentage (%). For subgroup analysis continuous variables are compared using the t-test or Mann-Whitney U test, when appropriate. All tests are two-sided and a P-value < 0.05 was determined to be significant.
For all determinants that might have an impact on the fault detection of the SpHb stepwise multiple regressions analysis was performed. Correlation is evaluated by Spearman rank test. To determine agreement of the methods, the Bland Altman analysis for repeated measurements is performed for SpHb and CoOcHb.
- Being tested
- Pulse CO-Oximetry Hemoglobin measurement transcutaneous
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulse CO-Oximetry Hemoglobin measurement transcutaneousDevice
Also called interventions are only performed based on co-oximetry hemoglobin measurement using a blood gas analyzer
this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
What is being measured
The primary outcome is the main question the study is designed to answer.
Reliability of SpHb to detect CoOxHb and its changes
Co-oximetry hemoglobin values from blood gas analyzer is simultaneous compared with the transcutaneous detected SpHb (Pulse CO-Oximetry hemoglobin measurement). Linear correlation and Bland Altman Analysis are performed for analysis these data pairs
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2020
- Study start1 Dec 2020 (estimated)
- Primary completion31 Dec 2021 (estimated)
- Study completion30 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Transcutaneous Continuous Hemoglobin MeasurementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Klinik Hirslanden, Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Werner Baulig, Klinik Hirslanden, Zurich
- Investigators
- Werner Baulig, MD, Principal investigator, Klinik Im Park
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04506957
- Sponsor's protocol ID
- Pulse-CO Oximetry Hemoglobin
- Acronym
- SpHb
- Status last verified
- Sep 2020
- First submitted
- 7 Aug 2020
- Last updated
- 4 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: it is not planned to make individual participant data available to other researchers
Publications
Baulig W, Seifert B, Spahn DR, Theusinger OM. Accuracy of non-invasive continuous total hemoglobin measurement by Pulse CO-Oximetry in severe traumatized and surgical bleeding patients. J Clin Monit Comput. 2017 Feb;31(1):177-185. doi: 10.1007/s10877-015-9816-2. Epub 2015 Dec 19.
PubMed 26686689
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Continuous Total Hemoglobin Measurement by Pulse CO-Oximetry in Major Spine Surgery
- ClinicalTrials.gov ID
- NCT04506957
- Acronym / sponsor ID
- SpHb / Pulse-CO Oximetry Hemoglobin
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Klinik Hirslanden, ZurichUniversity, hospital or other
- Study start
- 1 Dec 2020 (estimated)
- Primary completion
- 31 Dec 2021 (estimated)
- Study completion
- 30 Jun 2022 (estimated)
- First posted
- 10 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a data collection/sampling project for transcutaneous continuous Pulse CO-Oximetry and accessories (SW-Version Radical-7® Pulse CO-Oximeter with the Masimo rainbow SETTM, V1.6.2.4i Masimo Corp., Irvine, CA, USA, and the RD rainbow SET-2, Rev-O Fingersensor). The device received the CE Mark in 2012 and is approved by the Swiss Medic for clinical use. The Radical-7 device isolates multiple (7+) wavelengths of light of arterial signals using adaptive filters. It provides continuous noninvasive monitoring of arterial oxygen saturation (RadSpO2), pulse rate (RadPR), carboxyhaemoglobin saturation (SpCO), methaemoglobin saturation (SpMET), total haemoglobin concentration in g/dl (SpHb) and/or respiration rate (RRa). Additionally, Low Signal IQ (Low SIQ), Perfusion Index (PI), Pleth Variability Index (PVI), total arterial oxygen content (SpOC), Haematocrit (SpHCT), Signal identification Quality (SIQa), Respiration Indicator (RI) are displayed.The purpose of this prospective study is to investigate the reliability of non-invasive continuously measured SpHb by the Masimo Radical-7® Pulse co-oximeter (Radical 7 device) under steady state conditions by comparison against simultaneously invasive measured arterial haemoglobin concentrations (CoOxHb) in major spine surgery patients, in which high blood loss was expected
Detailed description
The objective of this investigation is the comparison of CoOxHb, HCT and SaO2 values of a blood gas analyzer (ABL 825, Radiometer Medical A/S) with simultaneously measured SpHb values of the Radical 7 device during the procedure of major spine surgery.
The primary endpoint of the study is the reliability of SpHb to detect CoOxHb and its changes during the process Secondary endpoint is the reliability of RadSpO2, RadPR, SpHCT and SpMET to detect SaO2, PR, HCT and MetHb and its changes during the process.
Inclusion criteria:
- Patients scheduled for major spine surger
- Age 18 years and older
- Written consent of the participation after clarification about the study
Exclusion criteria:
- No consent to participate
- No German comprehension
- Black skin patients
- Patients with COVID-19 illness All patients were monitored based on the institutional routine monitoring for major spine surgery (continuous 2-channel electrocardiogram, a continuous invasive arterial blood pressure monitoring via fluid-filled cather system, inserted in the radial artery mainly of the non-dominant hand, SpO2, and in the case of high-risk patient a triple-lumen central venous line). Then a single use finger sensor (MasimoSet RD rainbow SET SpHb SpMet-Sensor) is attahed to the ring finger of the hand, where the catheter is introduced in the radial artery.
During the surgery routinely, arterial blood samples are drawn before induction of Anaesthesia, every 45 min and after acute blood loss during surgery. With each blood sample for a blood gas analysis the SpHb, SpMet, PI, PVI and the low SQI are recorded.
No additional blood sampling is necessary to perfom this investigation
50 patients will be included and the duration of the study is 24 month's Sample size calculation was performed with the StatsDirect Statistical Software Version 2.8.0 2013 (StatsDirect Ltd, Altrincham, UK) and revealed a sample size of 95 paired SpHb and CoOxHb measurements to achieve a power of 0.9, α = 0.05 to detect a mean difference (bias) of CoOxHb and SpHb of 0.50 g/dl with an estimated standard deviation (SD) of 1.0g/dl. The mean difference is determined based on previous investigations. Continuous variables are tested for normal distribution with the Kolmogorov-Smirnow test. Normally distributed data are expressed as mean ± standard deviation (SD); median, interquartile range (IQR ; 25th to 75th percentile) and [maximum] are specified when the data were not normally distributed. Categorical variables are presented as number and percentage (%). For subgroup analysis continuous variables are compared using the t-test or Mann-Whitney U test, when appropriate. All tests are two-sided and a P-value < 0.05 was determined to be significant.
For all determinants that might have an impact on the fault detection of the SpHb stepwise multiple regressions analysis was performed. Correlation is evaluated by Spearman rank test. To determine agreement of the methods, the Bland Altman analysis for repeated measurements is performed for SpHb and CoOcHb.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 2 Years
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for major spine surgery
Key inclusion criteria (2 listed)
- Patients scheduled for major spine surgery
- Written consent of the participation after clarification about the study
Key exclusion criteria (4 listed)
- No consent to participate
- No German comprehension
- Black skin patients
- Patients with COVID-19 illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulse CO-Oximetry Hemoglobin measurement transcutaneousAlso: interventions are only performed based on co-oximetry hemoglobin measurement using a blood gas analyzerthis is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device | Device | – |
Primary outcome
Reliability of SpHb to detect CoOxHb and its changes
Time frame: 24 months
Co-oximetry hemoglobin values from blood gas analyzer is simultaneous compared with the transcutaneous detected SpHb (Pulse CO-Oximetry hemoglobin measurement). Linear correlation and Bland Altman Analysis are performed for analysis these data pairs
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2020.
- Background: PubMed 26686689Baulig W, Seifert B, Spahn DR, Theusinger OM. Accuracy of non-invasive continuous total hemoglobin measurement by Pulse CO-Oximetry in severe traumatized and surgical bleeding patients. J Clin Monit Comput. 2017 Feb;31(1):177-185. doi: 10.1007/s10877-015-9816-2. Epub 2015 Dec 19.
- Individual participant dataSharing planned: No. it is not planned to make individual participant data available to other researchers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Werner Baulig, MD principal investigator
Klinik Im Park
Questions about this trial
What is this clinical trial studying?
An observational study of Transcutaneous Continuous Hemoglobin Measurement, run by Klinik Hirslanden, Zurich.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Werner Baulig, MD (+41442092875, werner.baulig@hirslanden.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reliability of SpHb to detect CoOxHb and its changes (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04506957, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2020.